 WEST LAFAYETTE, Ind., April 16, 2021 GLOBE NEWSWIRE -- Inotiv, Inc. NASDAQ:NOTV the Company, We, Our or Inotiv, a leading provider of non-clinical and analytical contract research services, today announced that the Company has entered into an agreement and plan of merger with Bolder BioPATH, Inc. Bolder BioPATH, a contract pharmacology and pathology company specializing in in vivo models of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diseases of the central nervous system and other autoimmune, inflammation, and pain models. 